Search Results

Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project Officially Launched

On August 22, the groundbreaking ceremony for the Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project was held in Hengyang, Hunan Province. Officials from Hengyang City and Zhuhui District, representatives from relevant colleges of the University of South China, investment institutions, and relevant personnel from New Radiopharmaceutical Medical attended the event. Cai Jiming, Chairman and President of New Radiopharmaceutical Medical, stated at the ceremony that the project's landing in Hengyang represents an important strategic layout for the company's nuclear medicine business. From contract signing to construction commencement, the project has received support from local governments, partners, and relevant organizations. The company will leverage this project as an opportunity to continue advancing the transformation of innovative achievements in the fields of medical isotopes and radiopharmaceuticals. Wang Jing, Deputy Mayor of Hengyang City, stated that Hengyang...

2026-08-22

South Korea's Asan Medical Center Develops AI-Based Radiopharmaceutical Therapy Platform with U.S. Institutions

The research team at Asan Medical Center in Seoul announced on the 21st that it has recently been selected for the "2026 Korea-U.S. Innovative Outcomes R&D New Support Project" organized by the Ministry of Health and Welfare, and will collaborate with U.S. research institutions to develop an artificial intelligence-based radiopharmaceutical therapy platform aimed at exploring new treatment strategies for solid tumors that respond poorly to conventional therapies. The team is composed of professors including Myung Seung-jae from the Department of Gastroenterology, Oh Seung-jun from the Department of Nuclear Medicine, Ryu Chang-hoon from the Department of Oncology, Jung Byung-kwan from the Department of Pathology, and Son Byung-ho from the Department of Breast Surgery at Asan Medical Center. The project will combine Asan Medical Center's large-scale clinical and pathological data, Emory University's AI-based digital pathology analysis technology, and Case Western Reserve University and University Hospitals Cleveland Medical Center's pathological and clinical research capabilities.

2026-08-22

Armenia to Select Technology Solution for New Nuclear Power Plant by End of 2027

The Armenian government has set the end of 2027 as the deadline for selecting the technology solution for a new nuclear power plant. The project will eventually replace the existing Metsamor Nuclear Power Plant and has been incorporated into Armenia's government program for 2026 to 2031. According to the program, Armenia will advance the construction project for the new nuclear power plant and complete the reactor technology selection by at least the end of 2027. At present, the government has not yet disclosed the installed capacity, reactor type, or potential contractor for the new plant. Armenia has been evaluating nuclear power options from multiple countries in recent years, including both traditional large- or medium-sized nuclear units and small modular reactors (SMRs). Armenian officials have previously stated that units of relatively smaller scale, which are easier to connect to the national grid, are one of the key areas of focus for the government.

2026-08-23

Indiana University Health Establishes Center of Excellence in Theranostics to Advance Precision Targeted Cancer Therapy

Indiana University Health is establishing a new Center of Excellence in Theranostics, planning to provide cancer patients with more personalized diagnostic and treatment services through theranostic technologies. The project combines advanced medical imaging, precision diagnostics, and image-guided targeted therapy, aiming to enhance access to relevant medical services for patients in Indiana. Partial funding comes from a $20 million donor contribution, with Indiana University providing matching funds to bring total donations to $40 million. According to Indiana University, theranostics is a technological approach that integrates diagnosis and treatment. Clinically, advanced imaging techniques are first used...

2026-08-23

Iran Restarts Cyclotron to Boost Supply of Radiopharmaceuticals for Cancer Diagnosis and Treatment

Iranian nuclear industry experts have recently resumed operation of a cyclotron used in nuclear medicine, which can produce radioisotopes needed for cancer diagnosis and treatment. According to plans, by the end of Iran's Seventh Development Plan, i.e., March 2029, Iran will have seven such centers to expand domestic supply capacity for medical radioisotopes. A cyclotron is a type of particle accelerator that can be used to produce nuclear medicine radioisotopes and further prepare radiopharmaceuticals. These drugs can be used for the detection, diagnosis, and monitoring of malignant tumors. Data shows that related products produced domestically in Iran include FDG and F-PSMA, primarily serving nuclear medicine diagnosis and treatment for various cancers...

2026-08-21

Fire alarm triggered for sixth time in August at Japan's Fukushima Daiichi Nuclear Power Station; fire department confirms no fire occurred

At approximately 3:54 a.m. on August 21, a fire alarm was triggered on the first floor of the access control building at the Fukushima Daiichi Nuclear Power Station. Tokyo Electric Power Company (TEPCO) stated that no open flames or smoke were found near the site; shortly after 5:00 a.m., the fire department confirmed that the alarm was not caused by a fire. Readings from radiation monitoring stations around the plant also showed no significant fluctuations. This was the sixth fire alarm at the Fukushima Daiichi Nuclear Power Station since the beginning of August. Previously, the maintenance building for Units 5 and 6 triggered a fire alarm on August 8; the emergency diesel generator room for the high-pressure core spray system of Unit 6 triggered a fire alarm on August 12; the main administration building triggered a fire alarm on August 13...

2026-08-21

Atom High-Tech and CNNC Headway Visit Tsinghua University for Business Cooperation Exchange

On August 17, Luo Xu, General Manager of Atom High-Tech, and Liu Wen, Chairman of CNNC Headway, led a delegation to Tsinghua University for a business cooperation exchange with the School of Biomedical Engineering. Hu Ye, Dean of the School of Biomedical Engineering, and Ma Kai, Associate Professor of the School, attended the exchange. The visit aimed to leverage the research and talent advantages of a top-tier university, promote deep integration of industry, academia, and research, and jointly explore new cooperation opportunities in the fields of nuclear medicine and biomedical engineering. During the exchange meeting, Atom High-Tech and CNNC Headway respectively introduced their corporate development histories, core business layouts, and future strategic plans. Subsequently, Dean Hu Ye and Associate Professor Ma Kai respectively introduced...

2026-08-21

Brazilian CancerThera Delegation Visits Uruguay's CUDIM to Advance Theranostics Cooperation in Oncology

Following the institutional partnership established between CEPID CancerThera and the Uruguayan Center for Molecular Imaging (CUDIM) in February this year, a Brazilian delegation visited Montevideo, Uruguay, from July 27 to 29 to advance the transformation of the memorandum of understanding into a concrete work plan. The visit focused on multicenter clinical trials, preclinical research, theranostics in oncology, and educational cooperation. During the visit, Brazilian researchers held working meetings with the CUDIM team, covering multiple aspects of oncology research development. CUDIM was represented by its General Director Alarico Rodriguez, as well as radiopharmacist and Technical Director of Radiopharmacy, Dr. Eduardo Osvaldo Savio Queve...

2026-08-20

Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Radiopharmaceutical Development for Solid Tumors

Akiram Therapeutics, a Swedish clinical-stage biotechnology company, and ITM Isotope Technologies Munich SE, a German radiopharmaceutical biotechnology company, recently announced the signing of a supply agreement. Under the agreement, ITM will supply no-carrier-added lutetium-177 (nca Lu-177) to Akiram to support the clinical development of its targeted antibody-radionuclide conjugate, 177Lu-AKIR001 (AKIR001). AKIR001 is Akiram's lead radiopharmaceutical candidate, currently being investigated in clinical studies for the treatment of CD44v6-expressing solid tumors. The candidate combines the therapeutic radioisotope nca Lu-177 with a proprietary antibody targeting CD44v6. CD...

2026-08-20

Full-Life Technologies Completes Construction of Belgian Radiopharmaceutical Production Facility and Initiates Accelerator Commissioning

Full-Life Technologies (hereinafter referred to as "Full-Life"), a privately held, fully integrated, clinical-stage international radiopharmaceutical therapy company, announced on August 20 that its radiopharmaceutical production facility in Gembloux, Belgium, has completed construction and received authorization to commence accelerator commissioning and enter the initial ramp-up phase. (Full-Life Technologies Belgium Radiopharmaceutical Production Facility) This milestone marks a significant step forward in Full-Life's vertically integrated radioisotope production capabilities moving toward formal operational status. With the completion of facility construction, the company has entered the next phase of operational preparation, including accelerator installation, phased commissioning, and validation of critical safety and operational systems.

2026-08-20

Argonne National Laboratory's Nuclear Energy Operations Optimization Software Named Finalist for 2026 R&D 100 Awards

On August 18, 2026, multiple research projects from the U.S. Department of Energy (DOE) Argonne National Laboratory received recognition in the 2026 R&D 100 Awards. Among them, the open-source software FARM, directly related to nuclear energy system operations, was named a finalist, standing out as a noteworthy nuclear energy technology achievement among this year's winners and finalists. FARM stands for Feasible Actuator Range Modifier, jointly developed by Argonne National Laboratory and DOE's Idaho National Laboratory, with NuCube Energy Inc. as a collaborating partner. The software targets complex energy sy...

2026-08-19

Investigation into Automatic Shutdown of Unit 3 at Japan's Ohi Nuclear Power Plant: Damage Found in Exciter Rotating Rectifier

Kansai Electric Power reported on August 19 that Unit 3 of the Ohi Nuclear Power Plant experienced an automatic generator trip triggered by a generator loss-of-field alarm at 23:56 on August 8, followed by an automatic reactor shutdown. At the time of the event, the unit was operating stably at rated thermal power. The company stated that the event caused no radiological impact on the environment. The loss-of-field alarm is used to indicate an abnormal state in the magnetic field generated inside the generator. Following the incident, Kansai Electric conducted on-site inspections of equipment related to generator magnetic field establishment, including the generator, exciter, and automatic voltage regulator (AVR). Among these, the exciter is used to establish the magnetic field for the generator...

2026-08-19

Norway's Thor Medical AlphaOne High-Purity Alpha Radioisotope Facility to Be Officially Inaugurated

Thor Medical ASA announced on August 19 that its AlphaOne production facility at the Herøya industrial park in Norway will be officially inaugurated on September 9, 2026, with Norwegian Prime Minister Jonas Gahr Støre attending the ceremony. According to reports, AlphaOne is Thor Medical's first industrial-scale production facility for high-purity α radioisotopes and the first of its kind globally. The facility is already in operation, primarily producing isotope products for next-generation targeted cancer therapies, supplying high-purity α emitters to the radiopharmaceutical industry. Thor Medical CEO Jasper Kurth stated that AlphaOn...

2026-08-19

Dongcheng Pharmaceutical Adds New Radiopharmaceutical Production Center in Jinzhong, Shanxi

Recently, Shanxi Andike, a subsidiary of Dongcheng Andike, which is a wholly-owned subsidiary of Dongcheng Pharmaceutical, received the "Radiopharmaceutical Production License" issued by the Shanxi Provincial Drug Administration. This marks that the Jinzhong Radiopharmaceutical Production Center in Shanxi has met the requirements for commissioning, adding a new facility to Dongcheng Pharmaceutical's radiopharmaceutical production network. As one of China's leading nuclear medicine companies, the group adheres to a layout strategy of "networked short half-life and base-based long half-life" production, and has established a domestically leading radiopharmaceutical production and distribution network. To date, the group has put 33 radiopharmaceutical production centers into operation. As a heparin expert and radiopharmaceutical pioneer, Dongcheng Pharmaceutical will continue to deepen its presence in the nuclear medicine field, striving to build a comprehensive Dongcheng nuclear medicine ecosystem...

2026-08-18

Fire alarm triggered for fifth time at Fukushima Daiichi Nuclear Power Station in August; no fire confirmed on site

At 7:14 a.m. on August 18, a fire alarm was triggered on the first basement floor of the turbine building of Unit 5 at the Fukushima Daiichi Nuclear Power Station. Tokyo Electric Power Company (TEPCO) stated that after fire department personnel arrived and conducted inspections, no fire was confirmed on site at 7:55 a.m. Readings from radiation monitoring stations around the plant showed no significant fluctuations. This was the fifth time a fire alarm had been triggered at the Fukushima Daiichi Nuclear Power Station since the beginning of August. Previously, related alarms had occurred on August 8 at the maintenance building for Units 5 and 6, on August 12 at the emergency diesel generator room for the high-pressure core spray system of Unit 6, on August 13 at the main administration building, and on August 15 at the southwest stairwell of the turbine building of Unit 5. After each of the above alarms was triggered, the fire department confirmed that no fire had occurred...

2026-08-18